Insulin-like growth factor I (IGF-I) is currently in clinical trials for treatment of amyotrophic lateral sclerosis (ALS) based on its neuroprotective effect on motor neurons [33]. Here, IGF1 is linked to amyotrophic lateral sclerosis.